ReviewJournal of clinical oncology : official journal of the American Society of Clinical Oncology2011
Cancer immunotherapy comes of age.
Review in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03578185 (Genomic Analysis to Identify a Predictive Biomarker for Immunotherapy), which is not on this map. Cited by 263 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Genomic Analysis to Identify a Predictive Biomarker for Immunotherapy
Who cites it
263 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Infusion-Related Reactions Among Cancer Patients Receiving Immune Checkpoint Inhibitors: The ARON-MOUSEION-013 Systematic Review and Meta-Analysis.Drug design, development and therapy · 2025Pooled it
- Current status and challenges of immunotherapy in ALK rearranged NSCLC.Frontiers in oncology · 2022Pooled it
- Pooled it
- Anti-PD-1/PD-L1 Therapy as a Promising Option for Non-Small Cell Lung Cancer: a Single arm Meta-Analysis.Pathology oncology research : POR · 2016Pooled it
- Surv-CRM-12: A Bayesian phase I/II survival CRM for right-censored toxicity endpoints with competing disease progression.Statistics in medicine · 2022Trial
- SCI: A Bayesian adaptive phase I/II dose-finding design accounting for semi-competing risks outcomes for immunotherapy trials.Pharmaceutical statistics · 2022Trial
- A Bayesian phase I/II biomarker-based design for identifying subgroup-specific optimal dose for immunotherapy.Statistical methods in medical research · 2022Trial
- Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2015Trial
- Immunotherapeutic Approaches to Head and Neck Squamous Cell Carcinoma: Current Clinical Practice and Future Directions.Head & neck · 2026Review
- Remote-Controllable Immune-Priming Spot Formation Via Nanocomplexed Hydrogel-Assisted Histotripsy: Immunoasis.Advanced materials (Deerfield Beach, Fla.) · 2026Article
- XOR-mediated tumor-selective nanomaterial therapy: achieving tumor and immune cell dual regulation through intracellular ROS generation.Journal of nanobiotechnology · 2026Article
- Article
- A Multifunctional Metal-Based Nanomedicine for Copper Sequestration, in situ Toxification, and Immune Activation Against Metastatic Cancer.International journal of nanomedicine · 2026Article
- FLASH radiotherapy as an emerging paradigm in radioimmunotherapy: biological rationale, preclinical evidence, and translational roadmap.Frontiers in immunology · 2026Review
- Targeting VISTA as a novel immunotherapy for skin cancer.Frontiers in immunology · 2026Review
- Neoadjuvant immunotherapy in squamous cell carcinoma of the head and neck: current evidence and future perspectives.Molecular cancer · 2025Review
- Article
- Tumor Microenvironment: Recent Advances in Immunotherapies of Pancreatic Cancer.Medicina (Kaunas, Lithuania) · 2025Review
- Synergistic targeting strategies for prostate cancer.Nature reviews. Urology · 2025Review
- A randomized Bayesian phase I-II dose optimization design for combination cancer therapies with progression-free survival end point.BMC medical research methodology · 2025Article
203 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Cancer immunotherapy comprises a variety of treatment approaches, incorporating the tremendous specificity of the adaptive immune system (T cells and antibodies) as well as the diverse and potent cytotoxic weaponry of both adaptive and innate immunity. Immunotherapy strategies include antitumor monoclonal antibodies, cancer vaccines, adoptive transfer of ex vivo activated T and natural killer cells, and administration of antibodies or recombinant proteins that either costimulate immune cells or block immune inhibitory pathways (so-called immune checkpoints). Although clear clinical efficacy has been demonstrated with antitumor antibodies since the late 1990s, other immunotherapies had not been shown to be effective until recently, when a spate of successes established the broad potential of this therapeutic modality. These successes are based on fundamental scientific advances demonstrating the toleragenic nature of cancer and the pivotal role of the tumor immune microenvironment in suppressing antitumor immunity. New therapies based on a sophisticated knowledge of immune-suppressive cells, soluble factors, and signaling pathways are designed to break tolerance and reactivate antitumor immunity to induce potent, long-lasting responses. Preclinical models indicate the importance of a complex integrated immune response in eliminating established tumors and validate the exploration of combinatorial treatment regimens, which are anticipated to be far more effective than monotherapies. Unlike conventional cancer therapies, most immunotherapies are active and dynamic, capable of inducing immune memory to propagate a successful rebalancing of the equilibrium between tumor and host.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.